X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs DR. REDDYS LAB - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS DR. REDDYS LAB NOVARTIS/
DR. REDDYS LAB
 
P/E (TTM) x 347.8 27.3 1,275.9% View Chart
P/BV x 17.1 2.8 609.8% View Chart
Dividend Yield % 1.7 1.0 167.1%  

Financials

 NOVARTIS   DR. REDDYS LAB
EQUITY SHARE DATA
    NOVARTIS
Mar-16
DR. REDDYS LAB
Mar-16
NOVARTIS/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs9824,383 22.4%   
Low Rs5562,750 20.2%   
Sales per share (Unadj.) Rs252.9920.1 27.5%  
Earnings per share (Unadj.) Rs62.1126.1 49.3%  
Cash flow per share (Unadj.) Rs63.3183.0 34.6%  
Dividends per share (Unadj.) Rs10.0020.00 50.0%  
Dividend yield (eoy) %1.30.6 231.9%  
Book value per share (Unadj.) Rs363.6685.8 53.0%  
Shares outstanding (eoy) m31.96170.61 18.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.03.9 78.5%   
Avg P/E ratio x12.428.3 43.8%  
P/CF ratio (eoy) x12.219.5 62.3%  
Price / Book Value ratio x2.15.2 40.7%  
Dividend payout %16.115.9 101.5%   
Avg Mkt Cap Rs m24,580608,481 4.0%   
No. of employees `0000.821.7 3.5%   
Total wages/salary Rs m1,80131,874 5.7%   
Avg. sales/employee Rs Th10,748.97,244.4 148.4%   
Avg. wages/employee Rs Th2,395.21,470.9 162.8%   
Avg. net profit/employee Rs Th2,641.1992.8 266.0%   
INCOME DATA
Net Sales Rs m8,083156,978 5.1%  
Other income Rs m8292,693 30.8%   
Total revenues Rs m8,913159,671 5.6%   
Gross profit Rs m23434,587 0.7%  
Depreciation Rs m379,705 0.4%   
Interest Rs m2824 0.2%   
Profit before tax Rs m1,02526,751 3.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m170-   
Extraordinary Inc (Exp) Rs m1,6960-   
Tax Rs m7525,237 14.4%   
Profit after tax Rs m1,98621,514 9.2%  
Gross profit margin %2.922.0 13.2%  
Effective tax rate %73.419.6 374.7%   
Net profit margin %24.613.7 179.3%  
BALANCE SHEET DATA
Current assets Rs m12,678118,201 10.7%   
Current liabilities Rs m2,43368,368 3.6%   
Net working cap to sales %126.731.7 399.2%  
Current ratio x5.21.7 301.4%  
Inventory Days Days3360 54.5%  
Debtors Days Days2297 23.2%  
Net fixed assets Rs m6972,265 0.1%   
Share capital Rs m160853 18.7%   
"Free" reserves Rs m11,460111,548 10.3%   
Net worth Rs m11,621117,009 9.9%   
Long term debt Rs m010,690 0.0%   
Total assets Rs m14,400200,104 7.2%  
Interest coverage x570.533.5 1,704.8%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x0.60.8 71.6%   
Return on assets %13.811.2 123.7%  
Return on equity %17.118.4 92.9%  
Return on capital %23.621.6 109.2%  
Exports to sales %0.746.3 1.6%   
Imports to sales %18.69.0 207.7%   
Exports (fob) Rs m6072,618 0.1%   
Imports (cif) Rs m1,50314,050 10.7%   
Fx inflow Rs m18675,405 0.2%   
Fx outflow Rs m1,82127,115 6.7%   
Net fx Rs m-1,63548,290 -3.4%   
CASH FLOW
From Operations Rs m2,53140,476 6.3%  
From Investments Rs m-8,270-19,421 42.6%  
From Financial Activity Rs m-386-17,009 2.3%  
Net Cashflow Rs m-6,1254,046 -151.4%  

Share Holding

Indian Promoters % 0.0 25.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 5.4 37.0%  
FIIs % 1.6 35.3 4.5%  
ADR/GDR % 0.0 18.5 -  
Free float % 21.5 15.3 140.5%  
Shareholders   41,647 75,885 54.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   UNICHEM LAB  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  GLENMARK PHARMA  SUN PHARMA  

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Aug 18, 2017 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - AJANTA PHARMA COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS